NYSE: BMAMacro Bank Inc Stock
$74.19-3.75 (-4.81%)
Updated Jun 13, 2025
BMA Price
$74.19
Fair Value Price
N/A
Market Cap
$4.74B
52 Week Low
$42.23
52 Week High
$118.42
P/E
16.31x
P/B
1.31x
P/S
1.39x
PEG
0.26x
Dividend Yield
7.15%
Revenue
$4.11B
Earnings
$316.67M
Gross Margin
100%
Operating Margin
7.83%
Profit Margin
7.1%
Debt to Equity
2.58
Operating Cash Flow
$2B
Beta
1.09
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BMA Overview
Macro Bank Inc. is a private bank in Argentina. Macro Bank began operations as Financiera Macro, a brokerage specializing in arbitrage in 1976. It serves retail customers (individuals) and small, medium, and large corporate customers. In addition, Macro Bank also provides services to four Argentinian provincial governments. The bank is headquartered in Buenos Aires, Argentina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BMA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Bank
Industry Rating
D
BMA
Ranked#45 of 296
Ranked#45 of 296
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $34.81 | A | |
| $36.01 | B | |
| $14.40 | B |
Be the first to know about important BMA news, forecast changes, insider trades & much more!
BMA News
Overview
Due Diligence Score
–
Industry Average (35)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BMA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BMA ($74.19) is trading below its intrinsic value of $123.85, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BMA is good value based on its earnings relative to its share price (16.31x), compared to the US market average (31.36x)
P/E vs Market Valuation
BMA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more BMA due diligence checks available for Premium users.
Valuation
BMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
16.31x
Industry
11.9x
Market
31.36x
BMA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BMA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
BMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.31x
Industry
1.15x
BMA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BMA price to earnings growth (PEG)
For valuing profitable companies with growth potential
BMA is good value based... subscribe to Premium to read more.
PEG Value Valuation
BMA's financial health
Profit margin
Revenue
$4.5B
Net Income
$316.7M
Profit Margin
7.1%
BMA's Earnings (EBIT) of $321.82M... subscribe to Premium to read more.
Interest Coverage Financials
BMA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.1B
Liabilities
$10.1B
Debt to equity
2.58
BMA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.9B
Investing
-$129.7M
Financing
-$574.2M
BMA's operating cash flow ($1.79B)... subscribe to Premium to read more.
Debt Coverage Financials
BMA vs Bank Stocks
Macro Bank Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.